Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma

International Journal of Cancer

Volumn 98, Issue 6, 2002, Pages 916-922

  Tam, Henry K ^a   Zhang, Zuo Feng ^a   Jacobson, Lisa P ^b   Margolick, Joseph B ^b   Chmiel, Joan S ^c   Rinaldo, Charles ^d   Detels, Roger ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Highly active antiretroviral therapy; Kaposi sarcoma; Multicenter AIDS Cohort Study; Non Hodgkin lymphoma; Relative hazards; Survival

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; INDINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; PROSPECTIVE STUDIES; SARCOMA, KAPOSI; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037140112     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10274     Document Type: Article

References (46)

1. AIDS-associated malignancies
2. Combination antiretroviral therapy and incidence of AIDS-related malignancies
3. Impact of potent antiretroviral therapy on the incidence of Kaposi sarcoma and non-Hodgkin lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study
4. Kaposi sarcoma and non-Hodgkin lymphoma incidence trends in AIDS Clinical Trial Group study participants
5. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults
6. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
7. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
8. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
9. Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi sarcoma after highly active antiretroviral therapy
10. Regression of AIDS-related Kaposi sarcoma following antiretroviral therapy with protease inhibitors: Biological correlates of clinical outcome
11. Regression of AIDS-related Kaposi sarcoma following treatment with an HIV-1 protease inhibitor
12. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy
13. Evolving characteristics of AIDS-related lymphoma
14. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy
15. The Multicenter AIDS Cohort Study: Rationale organization and selected characteristics of the participants
16. Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study
17. Recent scientific contributions to understanding HIV/AIDS from the Multicenter AIDS Cohort Study
18. The Multicenter AIDS Cohort Study: Retention after 9.5 years
19. Report of NIH Panel to define principles of therapy of HIV infection and guidelines for the use of anti-retroviral agents in HIV-infected adults and adolescents
20. Nonparametric estimation from incomplete observations
21. Regression models and life tables
22. AIDS-associated non-Hodgkin lymphoma in San Francisco
23. Survival of AIDS patients according to type of AIDS-defining event
24. Changes in survival after acquired immunodeficiency syndrome (AIDS): 1984-91
25. Prognosis of Kaposi sarcoma as an initial and later AIDS associated illness
26. Clinical variants and staging of Kaposi sarcoma
27. Epidemiology of AIDS-related Kaposi sarcoma in Europe over 10 years
28. Effect of highly active antiretroviral therapy on survival in patients with aids-associated pulmonary Kaposi sarcoma treated with chemotherapy
29. Acquired immunodeficiency syndrome-related Kaposi sarcoma regression after highly active antiretroviral therapy: Biologic correlates of clinical outcome
30. The evaluation of human herpesvirus 8 (Kaposi sarcoma-associated herpesvirus) in cutaneous lesions of Kaposi sarcoma: A study of formalin-fixed paraffin-embedded tissue
31. Identification of HHV8 in early Kaposi sarcoma: Implications for Kaposi sarcoma pathogenesis
32. Human herpesvirus 8 seropositivity and risk of Kaposi sarcoma and other acquired immunodeficiency syndrome-related diseases
33. Effect of human immunodeficiency virus-1 protease inhibitors on the clearance of human herpesvirus 8 from blood of human immunodeficiency virus-1-infected patients
34. Identification of human herpesvirus 8-specific cytotoxic T-cell responses
35. + cytotoxic T lymphocyte responses to lytic proteins of human herpes virus 8 in human immunodeficiency virus type 1-infected and -uninfected individuals
36. Human herpesvirus 8 cellular immune responses in homosexual men
37. Resolution of severe Kaposi sarcoma after initiation of antiretroviral triple therapy
38. Long-term remission of AIDS-related primary central nervous system lymphoma associated with highly active antiretroviral therapy
39. Highly active antiretroviral therapy (HAART) and prolonged survival of a patient with an HIV-related Burkitt lymphoma, despite an intracardiac relapse
40. Lymphoma associated with human immunodeficiency virus infection
41. Improved prognosis in patients with acquired immunodeficiency syndrome-related lymphoma
42. Concomitant cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma
43. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone
44. + lymphocytes as prognostic markers of HIV-1 infection
45. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel